Rifapentine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Rifapentine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
105
Registered trials
38
Result records
6
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Rifapentine can convert its Small molecule drug profile and rpoB biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Rifapentine (query alias: rifapentine) |
|---|---|
| Modality / target | Small molecule drug; rpoB; rpoB inhibitors |
| Highest global status | Approved |
| Originator | Sanofi |
| Active developers | Centers for Disease Control & Prevention, The Johns Hopkins University, Macleods Pharmaceuticals Ltd. |
The MCP disease footprint includes Pulmonary Tuberculosis, Tuberculosis, Tuberculosis, Lymph Node. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07595042 | Phase 2 | Not yet recruiting | 900 | Lower-risk group: Proportion of participants with sustained cure at 52 weeks after randomization |
| ChiCTR2600124251 | Not Applicable | Not yet recruiting | 1009 | Incidence of tuberculosis |
| ChiCTR2600122596 | Not Applicable | Pending | 297 | Relapse-free cure at PT-M12 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children Receiving Once Weekly Rifapentine and Isoniazid for the Treatment of Latent Tuberculosis Infection
Not Applicable; n=158; evaluation: not stated. Reported fields: Rifapentine Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, AUC0-inf(Geometric Mean) = 650 mcg*h/mL (90% Confidence Interval, 604 - 699); Rifapentine Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, AUC0-inf(Geometric Mean): P-Value = <0.0001; Rifapentine Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, AUC0-inf(Geometric Mean): P-Value = <0.0001
Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial
Phase 4; n=500; evaluation: Negative. Reported fields: Treatment completion = 84.1 % ; Treatment completion = 89.6 %
Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB)
Phase 3; n=279; evaluation: Positive. Reported fields: Active TB rate = 1.67 cases per 100 person-years
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Rifapentine addresses Pulmonary Tuberculosis, Tuberculosis, Tuberculosis, Lymph Node. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: rpoB records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-07-09 | RedHill Biopharma Terminates License Agreement for Aemcolo® | Approved | US$12.0M upfront; US$100.0M milestones |
| 2023-09-04 | Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma | Approved | Financial terms not disclosed |
| 2023-09-04 | Adalvo and Cosmo partner up and launch Rifamycin SV MMX 200mg (Aemcolo®) in Europe, APAC, MENA and LATAM regions | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Rifapentine nasal spray and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Rifapentine powder injection and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “New application of rifapentine”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
